DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen

Information source: Hospital Universitario Pedro Ernesto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Antiphospholipid Antibody Syndrome

Intervention: Celecoxib (Drug); Acetaminophen (Drug); Rofecoxib (Drug); placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Hospital Universitario Pedro Ernesto

Official(s) and/or principal investigator(s):
Veronica S Vilela, MD, Principal Investigator, Affiliation: Hospital Universitario Pedro Ernesto


Coumadin drug-drug interactions (DDI) are frequent. Patients in permanent use of coumadin are advised to avoid traditional nonsteroidal antiinflammatory drugs to avoid risk of bleeding. New selctive cyclooxygesase 2 inhibitors arisen as potential option for treating pain and inflamation in these patients once interactions with coumadin are supposed to be lower. The CI(R)CA study was made to evaluate in a prospective fashion the occurrence of DDI with new cyclooxygenase antiinflammatory drugs and coumadin when compared to acetaminophen and placebo.

Clinical Details

Official title: CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen. A Prospective Double-blind, Placebo Controlled Study.

Study design: Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: International Normalized Ratio

Detailed description: The CI(R)CA study included patient diagnosed with antiphospholipid syndrome in permanent use of coumadin. Eligible patients were invited to use in a prospective cross-over mode two weeks of celecoxib, rofecoxib, acetaminophen and placebo with two weeks of wash out between drugs. Their international normalized ratio (INR) were measured before and during the use of each study drug. The interaction with coumadin was evaluated according to increases or decreases on the INR after each medication.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- PAPS on contious stable dose of coumadin

- 18 years old or older

- Younger than 65 yo

- Signed informed consent.

Exclusion Criteria:

- Renal failure

- Heart failure

- Symptomatic gastritis or peptic ulcer

- Elevated liver enzymes (>3 fold)

- Platelet count < 100,000.

Locations and Contacts

Additional Information

Starting date: March 2003
Last updated: January 6, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017